GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinogen Medical Ltd (FRA:3AC) » Definitions » EV-to-FCF

Actinogen Medical (FRA:3AC) EV-to-FCF : -4.99 (As of May. 05, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Actinogen Medical EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Actinogen Medical's Enterprise Value is €38.60 Mil. Actinogen Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.74 Mil. Therefore, Actinogen Medical's EV-to-FCF for today is -4.99.

The historical rank and industry rank for Actinogen Medical's EV-to-FCF or its related term are showing as below:

FRA:3AC' s EV-to-FCF Range Over the Past 10 Years
Min: -7.77   Med: -1.93   Max: -0.06
Current: -5.02

During the past 13 years, the highest EV-to-FCF of Actinogen Medical was -0.06. The lowest was -7.77. And the median was -1.93.

FRA:3AC's EV-to-FCF is ranked worse than
100% of 392 companies
in the Biotechnology industry
Industry Median: 4.57 vs FRA:3AC: -5.02

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-05), Actinogen Medical's stock price is €0.02. Actinogen Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.004. Therefore, Actinogen Medical's PE Ratio for today is At Loss.


Actinogen Medical EV-to-FCF Historical Data

The historical data trend for Actinogen Medical's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Actinogen Medical EV-to-FCF Chart

Actinogen Medical Annual Data
Trend Jun13 Jun14 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.34 -6.91 -117.16 -7.73 -7.36

Actinogen Medical Semi-Annual Data
Dec13 Jun14 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -7.73 - -7.36 -

Competitive Comparison of Actinogen Medical's EV-to-FCF

For the Biotechnology subindustry, Actinogen Medical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Actinogen Medical's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinogen Medical's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Actinogen Medical's EV-to-FCF falls into.



Actinogen Medical EV-to-FCF Calculation

Actinogen Medical's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=38.602/-7.741
=-4.99

Actinogen Medical's current Enterprise Value is €38.60 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Actinogen Medical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-7.74 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Actinogen Medical  (FRA:3AC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Actinogen Medical's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.02/-0.004
=At Loss

Actinogen Medical's share price for today is €0.02.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Actinogen Medical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.004.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Actinogen Medical EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Actinogen Medical's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Actinogen Medical (FRA:3AC) Business Description

Traded in Other Exchanges
Address
109 Pitt Street, Level 9, Suite 901, Sydney, NSW, AUS, 2000
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. Geographically, it operates and derives revenue from Australia. It has developed a product Xanamem.

Actinogen Medical (FRA:3AC) Headlines

No Headlines